This “Clinician POV” with Joshua Strauss, MD, a hematologist-oncologist with Advanced Care Hematology & Oncology Associates in New Jersey, discusses the available formulations of parenteral iron and their respective risks for hypophosphatemia, patient- and disease-related factors of the condition, administration of the formulations, monitoring, and more.

Blue sclera has an 87% to 89% sensitivity and a 64% to 94% specificity for iron deficiency anemia and iron deficiency in adults (ie, anemia need not always be present). Blue sclera has been reported, albeit infrequently, in other conditions such as rheumatoid arthritis, myasthenia gravis, and long-term steroid therapy.

The study, led by Michael Bretthauer, MD, PhD, of the University of Oslo in Norway, found that people who were invited to have a screening colonoscopy had a lower risk of colorectal cancer than those who were not, though at a lower rate than researchers expected. Furthermore, no significant difference in colorectal cancer-related mortality was discovered between the two groups.

The phase 1 EXPLORER and phase 2 PATHFINDER trials demonstrated that avapritinib can produce complete and long-lasting clinical responses as well as molecular remission in KIT D816V patients. The complex mutational landscape of AdvSM, which is frequently associated with a hematologic neoplasm, poses significant management challenges.

First-line pembrolizumab and pembrolizumab-chemotherapy continued to outperform cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma after a 4-year follow-up. Following pembrolizumab-based therapy, patients responded well to subsequent treatment.

This MashupMD link provides a video critique on YouTube of an NEJM paper on colonoscopy screening.